Interferon-Gamma Response Assays: ELISA and ELISPOT

The IFNG Response test toward M. Tuberculosis is modeled in the LB domain, in the TB-TAUG as the following:

ELISA:

ELISPOT:

There are several issues with this modeling:

1. Where do you show that this challenge assay is done against the TB antigens?
2. CP domain has developed a new standard variable called Test Condition Agent/CNDAGT, which is used to represent stimulating agents, like the values in ASSYAG above, should this variable be added to LB? CP Specification
   
3. Lastly, Interferon-Gamma Response Assay is a classic immunological test, is it correct to map this to the LB domain?
   
   1. Can we model this in the IS domain, see example dataset below.
   2. If we model this test in IS, how do we distinguish it from the INFg test in lab. Can we draw the line where if we are running a routine lab test looking for IFNg level it goes to LB vs. IFNg response test toward a specific, known bug then it goes to IS?
   3. If this test remains in LB, should NHOID be added to LB in order to show the name of the bug? I remember this being discussed by Jon/Bess when they worked on the TB TAUG.

If we were to model this in IS:

Similarly if we were to model Jozef's request in IS for https://loinc.org/95971-8/ --- SARS CoV-2 stimulated gamma interferon [Presence] in Blood